Cognitive Impairment Associated With SchizophreniaPhase 2TALLYNCT03745820
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)
A Phase 2 study testing BIIB104 in people with Cognitive Impairment Associated With Schizophrenia, run by Biogen at 60 sites in 5 countries.
Trial summary
The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery (MCCB). Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Cognitive Impairment Associated With Schizophrenia
- What is being tested?
- BIIB104
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 195 participants
- Where
- 60 sitesin 5 countries
- Study dates
- 15 Nov 2018to 7 Apr 2022
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Otherwise healthy participant with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), diagnosis of schizophrenia of at least 2 years' duration as confirmed by the mini-international neuropsychiatric interview (MINI) 7.0.2 for Psychotic Disorders.
- Evidence of stable schizophrenia symptomatology ≥12 weeks (e.g., no hospitalizations for schizophrenia, no increase in level of psychiatric care due to worsening of schizophrenia symptoms).
- Participants must be in ongoing maintenance atypical antipsychotic therapy (except clozapine), on a stable treatment regimen for ≥8 weeks prior to Baseline/Day 1, including concomitant psychotropic medication. Doses of background atypical antipsychotics should be within the recommended dose range listed in the approved product labeling of the country where the study is being conducted.
- SCI-PANSS: No more than moderate-severe rating (score ≤5) on delusions, hallucinatory behavior, grandiosity, suspiciousness / persecution, and hostility (i.e. PANSS, positive symptom items P1, P3, P5, P6, P7); or unusual thought content (G9); and no more than a moderate rating (score ≤4) on conceptual disorganization (P2).
Who cannot join
- Participation in a trial using any component or version of the MATRICS Consensus Cognitive Battery (MCCB) or the University of California, San Diego (UCSD) Performance-Based Skills Assessment test within the previous 6 months.
- Participation in cognitive remediation therapy within 6 months prior to randomization.
- Screening MCCB Working Memory Domain T-score ≥60.
- Current DSM-5 diagnosis of schizoaffective disorder on the MINI 7.0.2 for Psychotic Disorders.
- Current DSM-5 diagnosis of major depressive episode, manic and hypomanic episode, panic disorder, agoraphobia, social anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder, and/or generalized anxiety disorder on the MINI 7.0.2 for Psychotic Disorders.
- Lifetime DSM-5 diagnosis of antisocial personality disorder, anorexia nervosa, bulimia nervosa, and/or binge-eating disorder on the MINI 7.0.2 for Psychotic Disorders.
Show all 9Show fewer
- Meets the DSM-5 diagnosis of moderate or severe substance use disorder (excluding nicotine dependence) within 12 months of screening on the MINI 7.0.2 for Psychotic Disorders interview.
- DSM-5 diagnosis of Intellectual Disability (intellectual developmental disorder).
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Trial locations and contacts
60 sites in 5 countries.
60 sites in 5 countries
United States37 sites
Atlanta Center for Medical Research
Atlanta, Georgia, 30331
Augusta University
Augusta, Georgia, 30912
Pillar Clinical Research, LLC
Bentonville, Arkansas, 72712
Hassman Research Institute
Berlin, New Jersey, 08009
UB Department Psychiatry
Buffalo, New York, 104051
Neurobehavioral Research, Inc.
Cedarhurst, New York, 11516
Research Site
Chicago, Illinois, 60611
The Ohio State University Department of Psychiatry
Columbus, Ohio, 43210
ProScience Research Group
Culver City, California, 90230
Research Site
Decatur, Georgia, 30030
Research Site
Flowood, Mississippi, 39232
Research Site
Gaithersburg, Maryland, 20877
Collaborative Neuroscience Network, LLC
Garden Grove, California, 92845
Cherry Health
Grand Rapids, Michigan, 49503
Alexian Brothers Hospital Network
Hoffman Estates, Illinois, 60169
Research Site
Kirkland, Washington, 98033
Research Site
Lauderhill, Florida, 33319
Synergy San Diego
Lemon Grove, California, 91945
Research Site
Long Beach, California, 90807
Premier Clinical Research Institute, Inc.
Miami, Florida, 33122
Catalina Research Institute, LLC
Montclair, California, 91763
Yale University, Department of Psychiatry
New Haven, Connecticut, 06519
Research Site
North Canton, Ohio, 44720
Excell Research
Oceanside, California, 92056
Research Site
Pico Rivera, California, 90660
Research Site
Richardson, Texas, 75080
Finger Lakes Clinical Research
Rochester, New York, 14618
The University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78207
CNRI - San Diego, LLC
San Diego, California, 92102
Artemis Institute for Clinical Research
San Diego, California, 92103
Research Site
San Diego, California, 92123
Research Site
San Rafael, California, 94901
Southern Illinois University, School of Medicine
Springfield, Illinois, 62702
Research Site
St Louis, Missouri, 63128
St. Louis Clinical Trials, LC
St Louis, Missouri, 63141
Stedman Clinical Trials
Tampa, Florida, 33613
Research Site
Torrance, California, 90502
Japan9 sites
Research Site
Anan-shi
Research Site
Ichikawa-shi
Research Site
Kashihara-shi
Research Site
Kawasaki-shi
Research Site
Kita-gun
Research Site
Kodaira-shi
Research Site
Kumagaya-shi
Research Site
Takasaki-shi
Research Site
Yokosuka-shi
Spain7 sites
Hospital Clinic de Barcelona
Barcelona, 08036
Hospital Universitario 12 de Octubre
Madrid, 28040
Research Site
Majadahonda, Madrid, 28222
Research Site
Oviedo, Principality of Asturias, 33011
Unidad Neurociencias CS San Juan
Salamanca, 37005
Hospital Universitario Marques Valdecilla
Santander, Cantabria, 39008
Research Site
Seville, 41013
Germany4 sites
Zentrum für klinische Forschung Dr. med. I. Schöll
Bad Homburg, Hesse, 61348
Clinic for Psychiatrie
Frankfurt am Main, Hesse, 60528
Dpt of Psychiatry and Psychotherapy, University of Leipzig
Leipzig, Saxony, 04103
Universitätsmedizin Göttingen, Klinik für Psychiatrie und Psychotherapie
Westerstede, Lower Saxony, 26655
United Kingdom3 sites
Research Site
London, SE5 8AZ
Abraham Cowley Unit
Lyne, Surrey, KT16 0AE
Oxford Health NHS Foundation Trust
Oxford, Oxfordshire, OX3 7JX
About this study
Official title: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery (MCCB).
The secondary objectives of this study are to evaluate the safety and tolerability of BIIB104 in participants with CIAS, and to evaluate the efficacy of BIIB104 in participants with CIAS on measures of cognition, functioning, and psychiatric symptomology.
- Being tested
- BIIB104, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BIIB104Drug
Also called PF-04958242
Administered as specified in the treatment arm
PlaceboOther
Administered as specified in the treatment arm
| Study group | Role | What they receive |
|---|---|---|
| BIIB104 0.5 mg | Experimental | Participants will receive 0.5 mg of BIIB104 twice a day, orally, for 12 weeks. Receives: Drug: BIIB104 |
| BIIB104 0.15 mg | Experimental | Participants will receive 0.15 mg of BIIB104 twice a day, orally, for 12 weeks. Receives: Drug: BIIB104 |
| Matching Placebo | Placebo comparator | Participants will receive matching placebo twice a day, orally, for 12 weeks. Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Change From Baseline in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) Working Memory Domain Score at Week 12
The MCCB is a cognitive battery that assesses 7 domains recommended by the MATRICS initiative (i.e., Working Memory, Verbal Learning, Speed of Processing, Attention/Vigilance, Visual Learning, Social Cognition, and Reasoning and Problem Solving). MCCB was administered via laptop computer and paper-and-pencil assessments. T-scores for the individual tests were calculated according to the developer's recommended scoring algorithms. MCCB composite T scores are between 40 and 60 (normal range). Higher scores indicate better cognitive functioning. The working memory domain score of the MCCB is reported in this outcome measure.
Measured: Baseline and Week 12
Secondary outcomes (10)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in death, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or is a medically important event.
Measured: From first dose of study drug through end of the study (up to Week 14)
Mean Total Score Assessed by Scale for the Assessment and Rating of Ataxia (SARA)
The SARA is a clinical scale that is based on a semiquantitative assessment of cerebellar ataxia on an impairment level and complements the brief neurological examination. The SARA scale is an eight-item clinical rating scale (gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements, and heel-shin test) with a total score range of 0-40, where 0 is the best neurological status and 40 is the worst neurological status.
Measured: Baseline, Weeks 2, 6, 12 and safety follow-up (Week 14)
Number of Participants With at Least One Event of Suicidal Ideation and/or Suicidal Behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) Score
The C-SSRS is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods [not plan] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 6-item scale: 1 (actual attempt), 2 (interrupted attempt), 3 (aborted attempt), 4 (preparatory acts or behavior), 5 (suicidal behavior), and 6 (suicide). The data analyzed signifies the participants with at least one event of suicidal ideation and/or suicidal behavior.
Measured: Up to Week 14
Change From Baseline in University of California, San Diego Performance Based Skills Assessment-Brief International Version (UPSA-Bi) Assessment at Week 12
The UPSA-Bi, international version, an abbreviated version of the UPSA-Validation of Intermediate Measures, is a measure of functional capacity and assesses skills used in community tasks. This assessment measures 2 general skills that were previously identified as essential to functioning in the community: financial skills and communication skills. The UPSA-Bi assessment is scored from 0-100, higher scores indicating higher functional status.
Measured: Baseline and Week 12
Change From Baseline in Schizophrenia Cognition Rating Scale (SCoRS) Assessment Score at Week 12
The SCoRS is an interview-based assessment of cognition that involves interviews with participants and informants. The SCoRS includes 20 items designed to specifically assess aspects of cognitive functioning found in each of the seven MCCB cognitive domains including the following: Memory: 4 items; Learning: 2 items; Attention: 3 items; Working memory: 2 items; Problem solving: 3 items; Processing/motor speed: 2 items; Social cognition: 3 items; Language: 1 item. Total score range is 20-80, lower scores indicating higher functional status. The data reported in this outcome measure are for global rating score.
Measured: Baseline and Week 12
Change From Baseline in MCCB Neurocognitive Composite Scores at Week 12
The MCCB is a cognitive battery that assesses 7 domains recommended by the MATRICS initiative (i.e., Working Memory, Verbal Learning, Speed of Processing, Attention/Vigilance, Visual Learning, Social Cognition, and Reasoning and Problem Solving). MCCB was administered via laptop computer and paper-and-pencil assessments. T-scores for the individual tests were calculated according to the developer's recommended scoring algorithms. MCCB composite T scores are between 40 and 60 (normal range). Higher scores indicate better cognitive functioning. The MCCB composite score contains all of the tests and domains of the MCCB.
Measured: Baseline and Week 12
Change From Baseline in MCCB Individual Domain Scores (Excluding Working Memory Domain) at Week 12
The MCCB is a cognitive battery that assesses 7 domains recommended by the MATRICS initiative (i.e., working memory, verbal learning, speed of processing, attention/vigilance, visual learning, social cognition, and reasoning and problem solving). MCCB was administered via laptop computer and paper-and-pencil assessments. T-scores for the individual tests were calculated according to the developer's recommended scoring algorithms. MCCB composite T scores are between 40 and 60 (normal range). Higher scores indicate better cognitive functioning. All the domain scores of the MCCB are reported in this outcome measure with the exception of working memory domain.
Measured: Baseline and Week 12
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score, Positive Subscale, and Negative Subscale Scores at Week 12
The PANSS includes 3 subscales and 30 items: 7 items that make up the Positive subscale (e.g., delusions, conceptual disorganization, hallucinatory behaviour); 7 items that make up the Negative subscale (e.g., blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal); and 16 items that make up the General Psychopathology subscale (e.g., somatic concern, anxiety, guilt feelings, mannerisms and posturing, motor retardation, uncooperativeness, disorientation, poor impulse control, preoccupation). Each item on the positive, negative and general psychopathology subscale is rated from 1 (absent) to 7 (extreme). The score range is 7-49 for positive and negative subscales, score range is 16-112 for the general psychopathology subscale. Total PANSS score (positive+ negative + general psychopathology subscale scores) range from 30 to 210. Higher scores represent more severity in symptoms.
Measured: Baseline and Week 12
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scores at Week 12
The CGI-S consists of a single 7-point rating score of illness severity. The following question: "Considering your total clinical experience with this particular population, how mentally ill is your participant at this time?" is rated with a score from 1 to 7- 1: Normal, not ill at all; 2: Borderline mentally ill; 3: Mildly ill; 4: Moderately ill; 5: Markedly ill; 6: Severely ill; or 7: Among the most severely ill participants. Lower scores indicate less severity of illness.
Measured: Baseline and Week 12
Number of Participants With Response on Clinical Global Impression-Improvement (CGI-I) Scale at Week 12
The CGI-I consists of a single 7-point rating score total improvement, regardless of whether or not the change is due entirely to drug treatment. The following question: "Compared to your participant's condition at the beginning of treatment, how much has your participant changed?" is rated with a score from 1 to 7- 1: Very much improved; 2: Much improved; 3: Minimally improved; 4: No change; 5: Minimally worse; 6: Much worse; or 7: Very much worse. Lower scores indicate greater improvement.
Measured: Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2018
- Study start15 Nov 2018
- Primary completion23 Mar 2022
- Study completion7 Apr 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Cognitive Impairment Associated With SchizophreniaStudies of the same condition, open and under way.
- More trials run by BiogenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 195 participants (actual)
Sponsor and investigators
- Lead sponsor
- Biogen
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Medical Director, Study director, Biogen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03745820
- Sponsor's protocol ID
- 263CS201
- Other IDs
- 2018-003825-27, 2018
- Acronym
- TALLY
- Status last verified
- Mar 2023
- First submitted
- 15 Nov 2018
- Last updated
- 18 Apr 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
- ClinicalTrials.gov ID
- NCT03745820
- Acronym / sponsor ID
- TALLY / 263CS201
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 195 participants (actual)
- Lead sponsor
- BiogenIndustry (pharma, biotech, devices)
- Study start
- 15 Nov 2018 (actual)
- Primary completion
- 23 Mar 2022 (actual)
- Study completion
- 7 Apr 2022 (actual)
- First posted
- 19 Nov 2018 (actual)
- Results
- Posted 18 Apr 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery (MCCB).
The secondary objectives of this study are to evaluate the safety and tolerability of BIIB104 in participants with CIAS, and to evaluate the efficacy of BIIB104 in participants with CIAS on measures of cognition, functioning, and psychiatric symptomology.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| BIIB104 0.5 mg | Experimental | Drug: BIIB104Participants will receive 0.5 mg of BIIB104 twice a day, orally, for 12 weeks. |
| BIIB104 0.15 mg | Experimental | Drug: BIIB104Participants will receive 0.15 mg of BIIB104 twice a day, orally, for 12 weeks. |
| Matching Placebo | Placebo comparator | Other: PlaceboParticipants will receive matching placebo twice a day, orally, for 12 weeks. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Otherwise healthy participant with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), diagnosis of schizophrenia of at least 2 years' duration as confirmed by the mini-international neuropsychiatric interview (MINI) 7.0.2 for Psychotic Disorders.
- Evidence of stable schizophrenia symptomatology ≥12 weeks (e.g., no hospitalizations for schizophrenia, no increase in level of psychiatric care due to worsening of schizophrenia symptoms).
- Participants must be in ongoing maintenance atypical antipsychotic therapy (except clozapine), on a stable treatment regimen for ≥8 weeks prior to Baseline/Day 1, including concomitant psychotropic medication. Doses of background atypical antipsychotics should be within the recommended dose range listed in the approved product labeling of the country where the study is being conducted.
- SCI-PANSS: No more than moderate-severe rating (score ≤5) on delusions, hallucinatory behavior, grandiosity, suspiciousness / persecution, and hostility (i.e. PANSS, positive symptom items P1, P3, P5, P6, P7); or unusual thought content (G9); and no more than a moderate rating (score ≤4) on conceptual disorganization (P2).
Key exclusion criteria (9 listed)
- Participation in a trial using any component or version of the MATRICS Consensus Cognitive Battery (MCCB) or the University of California, San Diego (UCSD) Performance-Based Skills Assessment test within the previous 6 months.
- Participation in cognitive remediation therapy within 6 months prior to randomization.
- Screening MCCB Working Memory Domain T-score ≥60.
- Current DSM-5 diagnosis of schizoaffective disorder on the MINI 7.0.2 for Psychotic Disorders.
- Current DSM-5 diagnosis of major depressive episode, manic and hypomanic episode, panic disorder, agoraphobia, social anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder, and/or generalized anxiety disorder on the MINI 7.0.2 for Psychotic Disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BIIB104Also: PF-04958242Administered as specified in the treatment arm | Drug | BIIB104 0.15 mg, BIIB104 0.5 mg |
| PlaceboAdministered as specified in the treatment arm | Other | Matching Placebo |
Primary outcome
Change From Baseline in Change From Baseline in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) Working Memory Domain Score at Week 12
Time frame: Baseline and Week 12
The MCCB is a cognitive battery that assesses 7 domains recommended by the MATRICS initiative (i.e., Working Memory, Verbal Learning, Speed of Processing, Attention/Vigilance, Visual Learning, Social Cognition, and Reasoning and Problem Solving). MCCB was administered via laptop computer and paper-and-pencil assessments. T-scores for the individual tests were calculated according to the developer's recommended scoring algorithms. MCCB composite T scores are between 40 and 60 (normal range). Higher scores indicate better cognitive functioning. The working memory domain score of the MCCB is reported in this outcome measure.
10 secondary outcomes
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From first dose of study drug through end of the study (up to Week 14)
Mean Total Score Assessed by Scale for the Assessment and Rating of Ataxia (SARA)
Time frame: Baseline, Weeks 2, 6, 12 and safety follow-up (Week 14)
Number of Participants With at Least One Event of Suicidal Ideation and/or Suicidal Behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) Score
Time frame: Up to Week 14
Change From Baseline in University of California, San Diego Performance Based Skills Assessment-Brief International Version (UPSA-Bi) Assessment at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Schizophrenia Cognition Rating Scale (SCoRS) Assessment Score at Week 12
Time frame: Baseline and Week 12
Change From Baseline in MCCB Neurocognitive Composite Scores at Week 12
Time frame: Baseline and Week 12
Change From Baseline in MCCB Individual Domain Scores (Excluding Working Memory Domain) at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score, Positive Subscale, and Negative Subscale Scores at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scores at Week 12
Time frame: Baseline and Week 12
Number of Participants With Response on Clinical Global Impression-Improvement (CGI-I) Scale at Week 12
Time frame: Week 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Apr 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Cognitive Impairment Associated With Schizophrenia
Recruiting
Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use
Psychotic Disorders, Cannabis Use Disorder
Not yet recruiting
tDCS for Cognitive Impairment Associated With Recent-onset Schizophrenia
Schizophrenia, Psychotic Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Director study director
Biogen
60 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing BIIB104 in people with Cognitive Impairment Associated With Schizophrenia, run by Biogen at 60 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 60 sites in United States, Japan, Spain, Germany, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 18 Apr 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Change From Baseline in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) Working Memory Domain Score at Week 12 (time frame: Baseline and Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Apr 2023.